Clazosentan: First Approval

被引：12
作者：
Lee, Arnold [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2022年 / 82卷 / 06期
关键词：
ANEURYSMAL SUBARACHNOID HEMORRHAGE; ENDOTHELIN RECEPTOR ANTAGONIST; CEREBRAL VASOSPASM; CEREBROVASCULAR CHARACTERIZATION; DOUBLE-BLIND;
D O I：
10.1007/s40265-022-01708-0
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Clazosentan (PIVLAZ((TM))) is a small molecule, endothelin (ET) A receptor-selective antagonist being developed by Idorsia Pharmaceuticals. ETA receptor inhibition by clazosentan decreases ET-related cerebral vasospasm, which may occur after an aneurysmal subarachnoid haemorrhage. Clazosentan has been approved in Japan for use in the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischaemic symptoms after aneurysmal subarachnoid haemorrhage, following the results from the JapicCTI163369 and JapicCTI163368 phase III trials. This article summarises the milestones in the development of clazosentan leading to this first approval in this indication.
引用
收藏
页码：697 / 702
页数：6
相关论文
共 14 条
[1]   Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats [J].
Chen, Gang ;
Tariq, Asma ;
Ai, Jinglu ;
Sabri, Mohammed ;
Jeon, Hyo-jin ;
Tang, Elaine J. Y. ;
Lakovic, Katarina ;
Wan, Hoyee ;
Macdonald, R. Loch .
BRAIN RESEARCH, 2011, 1392 :132-139
[2]   Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients [J].
Fujimura, Miki ;
Joo, Jin-Yang ;
Kim, Jong-Soo ;
Hatta, Motonori ;
Yokoyama, Yoshinari ;
Tominaga, Teiji .
CEREBROVASCULAR DISEASES, 2017, 44 (1-2) :59-67
[3]   Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study [J].
Higashida, Randall T. ;
Bruder, Nicolas ;
Gupta, Rajiv ;
Guzman, Raphael ;
Hmissi, Abdel ;
Marr, Angelina ;
Mayer, Stephan A. ;
Roux, Sebastien ;
Weidauer, Stefan ;
Aldrich, E. Francois .
WORLD NEUROSURGERY, 2019, 128 :E639-E648
[4]  
Idorsia Pharmaceuticals, 2022, DAT FIL
[5]  
Idorsia Pharmaceuticals, 2022, PIVLAZ CLAZ 4 INF LI
[6]  
Johnson & Johnson, 2017, JOHNSON JOHNSON COMP
[7]   Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan [J].
Juif, Pierre-Eric ;
Dingemanse, Jasper ;
Voors-Pette, Christine ;
Ufer, Mike .
AAPS JOURNAL, 2020, 22 (05)
[8]   Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial [J].
Macdonald, R. Loch ;
Kassell, Neal F. ;
Mayer, Stephan ;
Ruefenacht, Daniel ;
Schmiedek, Peter ;
Weidauer, Stephan ;
Frey, Aline ;
Roux, Sebastien ;
Pasqualin, Alberto .
STROKE, 2008, 39 (11) :3015-3021
[9]   Randomised Trial of Clazosentan, an Endothelin Receptor Antagonist, in Patients with Aneurysmal Subarachnoid Hemorrhage Undergoing Surgical Clipping (CONSCIOUS-2) [J].
Macdonald, R. Loch ;
Higashida, Randall T. ;
Keller, Emanuela ;
Mayer, Stephan A. ;
Molyneux, Andy ;
Raabe, Andreas ;
Vajkoczy, Peter ;
Wanke, Isabel ;
Bach, Doris ;
Frey, Aline ;
Marr, Angelina ;
Roux, Sebastien ;
Kassell, Neal .
CEREBRAL VASOSPASM: NEUROVASCULAR EVENTS AFTER SUBARACHNOID HEMORRHAGE, 2013, 115 :27-+
[10]   Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling [J].
Macdonald, R. Loch ;
Higashida, Randall T. ;
Keller, Emanuela ;
Mayer, Stephan A. ;
Molyneux, Andy ;
Raabe, Andreas ;
Vajkoczy, Peter ;
Wanke, Isabel ;
Bach, Doris ;
Frey, Aline ;
Nowbakht, Pegah ;
Roux, Sebastien ;
Kassell, Neal .
STROKE, 2012, 43 (06) :1463-1469
12